Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company's primary mission lies in providing new options for patients with cancers driven by dysregulated gene expression, a hallmark of many aggressive cancer types. Salarius is advancing two main classes of therapeutics: targeted protein inhibitors (TPIs), exemplified by their lead candidate seclidemstat, which is undergoing phase 1/2 clinical trials; and targeted protein degraders (TPDs), with SP-3164 in preclinical development stages. These drug candidates are designed to modulate the abnormal activity of proteins that can activate cancer-promoting genes or silence tumor suppressor genes, thereby targeting the root mechanisms of cancer cell survival and proliferation. Operating from Houston, Texas, Salarius benefits from grant support by major research institutions, underlining its significance in the oncology sector. The company’s focus includes both solid and hematologic malignancies, potentially addressing unmet needs in diseases such as leukemia and lymphoma. Salarius Pharmaceuticals plays a key role in advancing the field of epigenetic cancer therapeutics and exemplifies the growing sector of precision medicine in the biotechnology industry.